clinical trial · NCT05412290
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
B Cell LymphomaAggressive LymphomaDiffuse Large B Cell LymphomaHigh-grade B-cell LymphomaTransformed LymphomaFollicular Lymphoma Grade 3Mosunetuzumab
brief summary
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
started
Dec 22, 2022
primary completion
Jan 31, 2027
completion
Aug 31, 2028
last updated
Apr 23, 2026
official title
A Pilot Study Evaluating the Safety and Efficacy of Mosunetuzumab Consolidation Therapy After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol